Investment Thesis

.

Competitive Moat

primarily through its intangible assets, including a strong brand reputation and a robust intellectual property portfolio. The company’s established regulatory relationships and extensive clinical trial experience further enhance its ability to launch new products successfully. This competitive advantage is expected to endure over the next 5-10 years, although threats from generic competition and emerging biopharma firms pose risks. Notably, the rise of biosimilars and advancements in gene therapies represent the most substantial competitive threats to its market share.

Growth Engine

Future revenue growth for Merck is anticipated to stem from a combination of a strong pipeline in oncology, particularly the ongoing success of Keytruda, and a resurgence in vaccine demand following recent global health crises. The total addressable market (TAM) for oncology is projected to expand significantly, fueled by increasing cancer incidence rates. Merck is also focusing on geographic expansion in emerging markets, which presents a substantial opportunity for organic growth. Furthermore, the company is strategically pursuing targeted acquisitions to enhance its product offerings, allowing it to gain market share in key therapeutic areas.